CClinicalTrials.gg
Not yet recruitingNCT07412418Updated May 1, 2026

Screening for Pulmonary Embolism Using Single-channel Electrocardiogram

An observational study in Pulmonary Embolism (Diagnosis), Respiratory Failure With Hypoxia and Chronic Obstructive Pulmonary Disease (COPD), sponsored by I.M. Sechenov First Moscow State Medical University. Not yet recruiting at 1 site in Russia. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by I.M. Sechenov First Moscow State Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample.

The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental).

During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.

All patients included in the study will undergo electrocardiogramm (ECG) in standart lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the Remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation. The result of this study will be the identification of ECG parameters that will correlate with pulmonary embolism.

Read the detailed description

The aim of the study: to create and evaluate the diagnostic efficiency of an algorithm for detecting pulmonary embolism using digital analysis of a single-channel ECG using elements of artificial intelligence. It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample). The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental). During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines.

All patients included in the study will undergo ECG recording in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. Single-channel ECG will be recorded using the portable single-lead ECG monitor CardioQvark. It is designed as an iPhone cover. It is registered with the Federal Service for Health Supervision on February 15, 2019. RZN No. 2019/8124.

The patient's personal data (last name, first name, patronymic, date of birth, contact information) will not be transferred or taken into account. Each patient is assigned an individual number that is not associated with his/her personal data. Then a spectral analysis of the electrocardiogram will be performed using a continuous wavelet transformation, the principles of which are based on the Fourier transform method. The analysis involves the evaluation of the following parameters (the parameters listed below will be calculated as the median of the tact-cycle):• TpTe - time from peak to end of the T-wave• VAT - time from the beginning of the QRS to the R-peak• QTc - corrected QT interval.• QT / TQ - the ratio of QT length to TQ length (from the end of T to the beginning of the QRS of the next complex).• QRS_E - the total energy of the QRS wave based on the wavelet transform• T_E - T-wave total energy based on wavelet transform• TP_E- energy of the main tooth of the T-wave based on the wavelet transform• BETA, BETA_S - T-wave asymmetry coefficients (simple and smooth versions)• BAD_T - flag of T-wave quality (whether expressed in the current lead• QRS_D1_ons - energy of the leading edge of the R-wave (based on the "first derivative" wavelet transform)• QRS_D1_offs - energy of the trailing edge of the R-wave (based on the "first derivative" wavelet transform)• QRS_D2 - peak energy of the R-wave (based on the "second derivative" wavelet transform)• QRS_Ei (i = 1,2,3,4) - QRS-wave energy in 4 frequency ranges (2-4-8-16-32 Hz) based on wavelet transform• T_Ei (i = 1,2,3,4) - T-wave energy in 4 frequency ranges (2-4-6-8-10 Hz) based on wavelet transform• HFQRS - the amplitude of the RF components of the QRS wave. Additionally used parameters:• TpTe, VAT, QTc - are duplicated to control the correctness of the record processing (the value of the UCC should be approximately equal to the median of the tick-by-bar).• QRSw - QRS width.• RA, SA, TA - the amplitudes of the R, S, T-waves, respectively, are used to normalize the parameters listed above.

Statistical analysis and modeling will be performed using Python V3.8.8 and R V.4.0, as well as SPSS v.17. The correlation between various combinations of ECG time, amplitude, energy, and frequency parameters and the presence or absence of PE will be analyzed. Specific parameters will be incorporated into various multivariate analysis and machine learning models: Lasso regression, random forest, multilayer perceptron, support vector machine, and decision tree. The model with the highest diagnostic accuracy will be selected and used to test the algorithm.

The outcome of this study will be the development and testing of an algorithm for pulmonary embolism detection using digital analysis of a single-channel ECG witj elements of artificial intelligence.

The endpoints of the study are the parameters of diagnostic accuracy of the developed model:

  • specificity,
  • sensitivity,
  • prognostic significance of a positive and negative result,
  • diagnostic accuracy. Тhese metrics will be calculated using receiver operating characteristic (ROC) analysis and confusion matrices on a held-out test set (30% of the dataset) after training multifactorial models (logistic regression, random forest, or neural networks) on single-lead ECG features. Sensitivity, specificity, positive/negative predictive values, and overall accuracy will be derived by comparing model predictions of pulmonary embolism against the gold standard, with cross-validation (k=5 folds) to ensure robustness and bootstrap resampling for 95% confidence intervals.
02

Conditions studied

  • Pulmonary Embolism (Diagnosis)
  • Respiratory Failure With Hypoxia
  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Screening
  • single-channel electrocardiogram
  • machine learning models
  • pulmonary embolism
  • respiratory failure
  • chronic obstructive pulmonary disease
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study is planned to include at least 500 patients 18 years old and older (300 patients in the training sample and 200 patients in the test sample. The study will include all patients requiring exclusion of the diagnosis of acute pulmonary embolism. Patients will be examined according to clinical guidelines to confirm the diagnosis of pulmonary embolism (laboratory, clinical and instrumental). During the course of the study, the authors of the work do not interfere with the scope of the examination, which is caried out on patients in accordance with clinical guidelines

Inclusion criteria

  1. A clinical condition requiring exclusion of acute pulmonary embolism;
  2. The presence of written informed consent of the patient to participate in the study;
  3. Age from 18 years old and older

Non-inclusion criteria:

  1. Refusal to undergo examination or the inability to reliably verify or exclude the diagnosis of pulmonary embolism;
  2. Treatment, in particular anticoagulant therapy, before recording a single-lead ECG;
  3. Conditions in which recording an ECG in lead I is not possible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs, tremor, etc.);
  4. Refusal to sign written informed consent to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Poor ECG quality, preventing the necessary analysis of a single-channel ECG;
  2. Incomplete examination, preventing a reliable determination of the presence or absence of pulmonary embolism;
  3. Refusal to further participate in the study.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Training sample

    300 patients 18 years old and older with and without pulmonary embolism confirmed by the results of full examination (laboratory, clinical and instrumental) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS\_E, T\_E, TP\_E, BETA, BETA\_S, BAD\_T, QRS\_D1\_ons, QRS\_D1\_offs, QRS\_D2, QRS\_Ei (i = 1,2,3,4), T\_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others).

  • Test sample

    200 patients 18 years old and older with and without pulmonary embolism confirmed by the results of full examination (laboratory, clinical and instrumental) and by results of the spectral analysis of electrocardiogram (the parameters listed below will be calculated as the median of the tact-cycle: TpTe, VAT, QTc, QT / TQ, QRS\_E, T\_E, TP\_E, BETA, BETA\_S, BAD\_T, QRS\_D1\_ons, QRS\_D1\_offs, QRS\_D2, QRS\_Ei (i = 1,2,3,4), T\_Ei (i= 1,2,3,4), HFQRS, QRSw, RA, SA, TA and others).

05

What researchers measure

Primary outcomes

  1. Determination of sensitivity of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Time frame: through study completion, an average of 2 years

  2. Parameters of single-channel ECG that significantly correlate with the presence of pulmonary embolism;

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Time frame: through study completion, an average of 2 years

  3. Determination of specificity of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Time frame: through study completion, an average of 2 years

  4. Determination of diagnostic accuracy of pulmonary embolism of multivariate models for analyzing single-channel electrocardiogram data

    comparison of the presence of pulmonary embolism by the results of full examination (laboratory, clinical and instrumental) with the results of the presence of pulmonary embolism obtained using the mathematical model of a single-channel ECG monitor

    Time frame: through study completion, an average of 2 years

06

Study locations

1 site
  • University Clinical Hospital №1, Sechenov University
    Moscow, Russia
07

References and documents

Individual participant data

Plan to share: No — It is not possible to provide documentation due to the prohibition received from the local ethics committee

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07412418
Lead sponsor
I.M. Sechenov First Moscow State Medical University
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
May 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Petr Chomakhidze, Professor
Contact
chomakhidze_p_sh@staff.sechenov.ru
+79166740369
Aliya Khusyainova, Dr.
Contact
khusyainova1997@bk.ru
+79832824402

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion